Joe Yanchik is the President and Chief Executive Officer of Aileron Therapeutics (Cambridge, MA) that he helped to found in June of 2005. Prior to Aileron, Mr. Yanchik was a founder and CEO of Tokai Pharmaceuticals, Venture Partner at Apple Tree Partners, Vice President of Corporate Development at Mendel Biotechnology and founder and Chief Business Officer of Poetic Genetics, Inc. Mr. Yanchik previously specialized in corporate and securities law at Cahill Gordon & Reindel (New York, NY) and Venture Law Group (Menlo Park, CA). He is presently on the Board of Directors of Tokai Pharmaceuticals.
Mr. Yanchik received a B.B.A. from Loyola College and received his J.D. with Honors from Villanova University School of Law, where he was Managing Editor of the Law Review.
Manuel Aivado has served as our Chief Medical Officer since October of 2014. Prior to joining Aileron, Dr. Aivado served as Taiho Oncology’s Vice President of Clinical Development and Pharmacovigilance. In that capacity, he built global clinical development capabilities, and led multiple drug programs ranging from phase 1 through phase 3, most prominently the global development of Teysuno® (S-1), TAS-102 and TAS-120. Prior to Taiho, Dr. Aivado held positions of increasing responsibility at GlaxoSmithKline, including as Senior Medical Director in the Clinical Development group, where he was involved in numerous drug programs including ofatumumab (Arzerra®), trametinib (Mekinist®), pazopanib (Votrient®), and eltrombopag (Promacta®). Prior to his industry experience, Dr. Aivado practiced ten years of clinical medicine in Germany. During his clinical career, he directed various molecular cancer research projects, which led him to be awarded the prestigious Dr. Mildred Scheel cancer research scholarship award in 2002. Dr. Aivado was previously an Instructor in Medicine at Beth Israel Deaconess Medical Center/Harvard Medical School, where he led the first ever-conducted proteomics research project in Myelodysplastic Syndromes (MDS). During his work in academia and in the pharmaceutical industry, Dr. Aivado’s work has culminated in more than 50 peer-reviewed papers, including research articles in Lancet, Nature Genetics and PNAS. Dr. Aivado is a member of the American Society of Hematology and a member of the American Society of Clinical Oncology.
Dr. Aivado is a German Board-certified physician for Internal Medicine, Hematology, and Medical Oncology, and he earned an M.D. and Ph.D. from the Medical School of the University of Dusseldorf, in Germany.
Mr. Lippman has served as our SVP, Chief Financial Officer & Business Officer since January 2015. He began his career in corporate finance and investment banking, managing equity, debt and M&A processes, working with such companies as Bank of America, and Bear Stearns. Prior to joining Aileron, Mr. Lippman was Senior Vice President at EMD Serono, Inc., leading the strategic direction of the US Neurology franchise, as well as managing its operations related to sales, marketing and support services. Mr. Lippman joined EMD Serono from AstraZeneca, where he served as Executive Director of the company’s multi-billion dollar brands, Crestor® and Nexium®, as well as the general Primary Care Portfolio. While at AstraZeneca, Mr. Lippman also held other roles including Head of US Business Development. Prior to AstraZeneca, he worked at Pfizer as Executive Director, Worldwide Business Development and Strategic Planning. Mr. Lippman holds a Bachelor of Arts in Political Science from Bucknell University, a Bachelor of Arts in Business from Georgia State University, and a Masters in Business Administration from Cornell University.
Allen Annis has served as our Senior Director of Biophysical and Analytical Technologies since November of 2007. He was previously Director of Technology Development at the Schering-Plough Research Institute in Cambridge, MA, and prior to that he was Vice President of New Technologies at NeoGenesis Pharmaceuticals, which was acquired by Schering in 2005. While at NeoGenesis, Dr. Annis co-developed its core drug discovery platform, the affinity selection-mass spectrometry-based Automated Ligand Identification System (ALIS). Dr. Annis authored several patents and publications that describe the ALIS technology, and invented many novel techniques that use ALIS to study protein-drug interactions.
Dr. Annis received his B.S. in chemistry from the Georgia Institute of Technology and received his Ph.D. in chemistry from Harvard University.
Donna Jarlenski has served as our Vice President of Clinical Operations and Program Management since October of 2014. Before joining Aileron, Ms. Jarlenski served as Senior Director, Clinical Development Execution, Global Medicines Development & Affairs at Vertex Pharmaceuticals, where she was responsible for general oversight, strategic budget and resource planning, and corporate alignment of five business units. Prior to Vertex, Ms. Jarlenski held drug development positions in several large and small biotechnology companies, including Tolerx, Inc., Purdue Pharma, and Sepracor, Inc. Previously, she also held clinical study management positions with PPD, Inc., MedcoResearch, Inc., and ClinTrials Research, Inc. She is a certified Project Manager Professional (PMP) through The Project Management Institute.
Ms. Jarlenski holds a BS degree in Microbiology from The Pennsylvania State University and is pursuing a Master of Science at Quinnipiac University.